Abstract
Scutellarin (1) possesses distinguished efficacy in the clinical therapy of cerebral infarction, coronary heart disease, and angina pectoris. Scutellarin (1) is readily converted in vivo, therefore, synthetic methods for the construction of its metabolites will be very important in the near future. In this work, an efficient and first synthetic method for 6-O-methyl- scutellarein (3), one metabolite of scutellarin in vivo, is developed. Dichlorodiphenylmethane in diphenyl ether is used firstly to protect the dihydroxy groups at C-6 and C-7 in scutellarein (2). Then, benzyl bromide is used to selectively protect the hydroxy groups at C-4' and C-7 in 10. 6-O-Methyl-scutellarein (3) is obtained in high yield through seven steps.
Keywords: 6-O-methyl-scutellarein, metabolite, scutellarin, synthesis, regioselective protection.
Letters in Organic Chemistry
Title:Efficient Synthesis of 6-O-methyl-scutellarein from Scutellarin via Selective Methylation
Volume: 10 Issue: 10
Author(s): Min-Zhe Shen, Zhi-Hao Shi, Nian-Guang Li, Hao -Tang, Qian-Ping Shi, Yu-Ping Tang, Jian-Ping Yang and Jin-Ao Duan
Affiliation:
Keywords: 6-O-methyl-scutellarein, metabolite, scutellarin, synthesis, regioselective protection.
Abstract: Scutellarin (1) possesses distinguished efficacy in the clinical therapy of cerebral infarction, coronary heart disease, and angina pectoris. Scutellarin (1) is readily converted in vivo, therefore, synthetic methods for the construction of its metabolites will be very important in the near future. In this work, an efficient and first synthetic method for 6-O-methyl- scutellarein (3), one metabolite of scutellarin in vivo, is developed. Dichlorodiphenylmethane in diphenyl ether is used firstly to protect the dihydroxy groups at C-6 and C-7 in scutellarein (2). Then, benzyl bromide is used to selectively protect the hydroxy groups at C-4' and C-7 in 10. 6-O-Methyl-scutellarein (3) is obtained in high yield through seven steps.
Export Options
About this article
Cite this article as:
Shen Min-Zhe, Shi Zhi-Hao, Li Nian-Guang, -Tang Hao, Shi Qian-Ping, Tang Yu-Ping, Yang Jian-Ping and Duan Jin-Ao, Efficient Synthesis of 6-O-methyl-scutellarein from Scutellarin via Selective Methylation, Letters in Organic Chemistry 2013; 10 (10) . https://dx.doi.org/10.2174/15701786113109990046
DOI https://dx.doi.org/10.2174/15701786113109990046 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives
Current Pharmaceutical Design Challenge of Mesenchymal Stem Cells Against Diabetic Foot Ulcer
Current Stem Cell Research & Therapy Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Benefits of Exercise Training in Secondary Prevention of Coronary and Peripheral Arterial Disease
Vascular Disease Prevention (Discontinued) Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research The Utility of Emerging Biomarkers and Imaging for Assessment of Cardiovascular Risk
Current Vascular Pharmacology The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins
Current Pharmaceutical Design Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]
Current Vascular Pharmacology Mediterranean Diet Rich in Olive Oil and Obesity, Metabolic Syndrome and Diabetes Mellitus
Current Pharmaceutical Design Effects of Immunosenescence on the Lower Expression of Surface Molecules in Neutrophils and Lymphocytes
Current Aging Science Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Folate and Homocysteine Metabolism: Therapeutic Targets in Cardiovascular and Neurodegenerative Disorders
Current Medicinal Chemistry The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis
Current Cardiology Reviews